Obesity Drugs Covered By One-Third Of Large Employers In Survey
This article was originally published in The Pink Sheet Daily
Executive Summary
The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.
You may also be interested in...
With Another Push From Eisai, Can Arena’s Belviq Be A Blockbuster?
The Japanese pharma has expanded its collaboration with Arena for the obesity treatment Belviq, but the drug is off to a slow start in a market full of non-starters.
Japan Earnings Highlights: New Products Win The Day For Top Pharma
PharmAsia News brings highlights from Japan’s week of earnings presentations.
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.